Literature DB >> 34004127

The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation.

Lida P Hariri1, Anja C Roden2, Jonathan H Chung3, Sonye K Danoff4, Diana C Gomez Manjarres5, Matthew Hartwig6, Fayez Kheir7, Christopher King8, Maryl Kreider9, David A Lynch10, Joshua Mooney11, Ashok Muniappan12, Jeffrey L Myers13, Luca Paoletti14, Rishi Raj15, Zeenat Safdar16, Sally Suliman17, Krishna Thavarajah18, David J Lederer19,20, Frederick L Rudell20, Pauline Bianchi20, Barry S Shea21, Brett Ley22,23.   

Abstract

Diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion approach that includes clinicians, radiologists, and pathologists. Surgical lung biopsy (SLB) is currently the recommended standard in obtaining pathologic specimens for patients with ILD requiring a tissue diagnosis. The increased diagnostic confidence and accuracy provided by microscopic pathology assessment of SLB specimens must be balanced with the associated risks in patients with ILD. This document was developed by the SLB Working Group of the Pulmonary Fibrosis Foundation, composed of a multidisciplinary group of ILD physicians, including pulmonologists, radiologists, pathologists, and thoracic surgeons. In this document, we present an up-to-date literature review of the indications, contraindications, risks, and alternatives to SLB in the diagnosis of fibrotic ILD; outline an integrated approach to the decision-making around SLB in the diagnosis of fibrotic ILD; and provide practical information to maximize the yield and safety of SLB.

Entities:  

Keywords:  diagnostic guidelines; idiopathic pulmonary fibrosis; interstitial lung disease; surgical lung biopsy; usual interstitial pneumonitis

Mesh:

Year:  2021        PMID: 34004127     DOI: 10.1513/AnnalsATS.202009-1179FR

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  1 in total

1.  Transbronchial Lung Cryobiopsy is Safe and Effective for Diagnosing Acutely Ill Hospitalized Patients with New Diffuse Parenchymal Lung Disease.

Authors:  Carson Castellani; Henry Castellani; Bryan S Benn
Journal:  Lung       Date:  2022-02-01       Impact factor: 3.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.